Tamer I Khayal sold $8.6M of TMDX
Chief Commercial Officer at TransMedics Group, Inc.. 78,036 shares at an average of $109.78, traded May 1, 2024, filed May 3, 2024.
Score components
- +15RoleOfficer
- +25Trade size$8.6M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +6.6%, 3m +17.3%, 6m -35.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-052962, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2024 | MOption exercise Common Stock10b5-1 | +45,326 | $38.46 | $1.7M | 70,511 | May 3, 2024 |
| May 1, 2024 | MOption exercise Common Stock10b5-1 | +1,458 | $38.46 | $56k | 71,969 | May 3, 2024 |
| May 1, 2024 | MOption exercise Common Stock10b5-1 | +1,083 | $13.28 | $14k | 73,052 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -23,231 | $105.96 | $2.5M | 49,821 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -12,250 | $107.00 | $1.3M | 37,571 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3,477 | $107.84 | $375k | 34,094 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -3,027 | $109.28 | $331k | 31,067 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -15,892 | $109.83 | $1.7M | 15,175 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -100 | $113.16 | $11k | 15,075 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -326 | $116.80 | $38k | 14,749 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -738 | $117.96 | $87k | 14,011 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1,259 | $118.93 | $150k | 12,752 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -1,799 | $119.85 | $216k | 10,953 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -512 | $120.86 | $62k | 10,441 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -532 | $121.74 | $65k | 9,909 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -17 | $122.51 | $2,083 | 9,892 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stock10b5-1 | -100 | $123.66 | $12k | 9,792 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stockindirect: By the Khayal Family 2021 Irrevocable Trust10b5-1 | -6,888 | $110.06 | $758k | 7,888 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stockindirect: By the Khayal Family 2021 Irrevocable Trust10b5-1 | -500 | $111.50 | $56k | 7,388 | May 3, 2024 |
| May 1, 2024 | SOpen-market sale Common Stockindirect: By the Khayal Family 2021 Irrevocable Trust10b5-1 | -7,388 | $120.01 | $887k | 0 | May 3, 2024 |
| May 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -45,326 | $0.00 | $0 | 16,042 | May 3, 2024 |
| May 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,458 | $0.00 | $0 | 14,584 | May 3, 2024 |
| May 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,083 | $0.00 | $0 | 23,834 | May 3, 2024 |
Related signals
Other insiders at TransMedics Group, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | TMDXbuy TransMedics Group, Inc. | David Weill director | $109k 1,336 shares | +9% | |
| 31Weak | TMDXsell TransMedics Group, Inc. | Thomas James Gunderson director | $722k 9,624 shares | -37% | |
| 52Moderate | TransMedics Group, Inc. | Stephanie Lovell director | $178k 1,193 shares | -29% | |
| 38Weak | TransMedics Group, Inc. | David Weill director | $524k 3,571 shares | -23% | |
| 46Moderate | TransMedics Group, Inc. | Nicholas Corcoran See remarks | $413k 2,966 shares | -9% | |
| 67Notable | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $1.1M 7,611 shares | -51% | |
| 40Moderate | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $120k 864 shares | -6% | |
| 48Moderate | TransMedics Group, Inc. | Gerardo Hernandez Chief Financial Officer | $128k 920 shares | -6% | |
| 46Moderate | TransMedics Group, Inc. | David Weill director | $693k 5,000 shares | -29% | |
| 37Weak | TransMedics Group, Inc. | Anil P. Ranganath See remarks | $436k 3,000 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.